Loading…
Loading…
The Amplify Weight Loss Drug & Treatment ETF (THNR) offers investors a way to access international firms poised to benefit financially from advancements in weight management pharmaceuticals. Its primary objective is to mirror the investment performance (before any fees or expenses) of the VettaFi Weight Loss Drug & Treatment Index.
Is THNR's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.
Novo Nordisk's CagriSema delivers 25% weight loss in women, spotlighting three ETFs for diversified exposure to the sector's growth.
REX Shares recently launched the REX Peptide ETF (PEPT), a thematic fund offering global exposure to the peptide industry, from drug developers to manufacturers and delivery platforms.
Healthcare stocks have finally stepped back into the spotlight. After spending much of the past several years in the shadow of technology and AI, the sector has quietly emerged as one of the year's more compelling comeback stories.
LLY and Novo face off at EASD as new data fuels the GLP-1 market, while ETFs offer diversified exposure to weight loss drug growth.
There is a myth that index-based ETFs are all static buy-and-hold products that passively track a benchmark. Many people think of indexing through the lens of market-cap strategies like the Vanguard S&P 500 ETF (VOO).